Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decline of 27.5% from the October 15th total of 48,700 shares. Based on an average daily volume of 31,100 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company's stock are sold short.
阿瓦洛治療公司(納斯達克代碼:AVTX-GET評級)在10月份看到空頭股數的銷售額大幅下降。截至10月31日,空頭股數共有35,300股,較10月15日的48,700股下降了27.5%。以日均成交量31,100股計算,目前短息比率為1.1天。目前,該公司0.4%的股票被賣空。
Avalo Therapeutics Trading Down 0.5 %
Avalo治療公司股價下跌0.5%
NASDAQ AVTX traded down $0.03 during trading on Monday, hitting $5.77. The company's stock had a trading volume of 6,065 shares, compared to its average volume of 41,556. The company has a debt-to-equity ratio of 5.23, a current ratio of 1.07 and a quick ratio of 0.97. The business's 50 day simple moving average is $4.92 and its 200-day simple moving average is $5.19. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $27.84.
在週一的交易中,納斯達克AVTX股價下跌0.03美元,至5.77美元。該公司股票的成交量為6,065股,而其平均成交量為41,556股。該公司的債務權益比為5.23,流動比率為1.07,速動比率為0.97。該業務的50日簡單移動均線切入位為4.92美元,200日簡單移動均線切入位為5.19美元。Avalo Treateutics的股價為52周低點2.42美元,52周高點27.84美元。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, Oppenheimer lowered their price target on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday, November 9th.
另外,奧本海默在11月9日星期三的一份報告中將Avalo治療公司的目標價從17.00美元下調至10.00美元。
Institutional Investors Weigh In On Avalo Therapeutics
機構投資者看好Avalo治療公司
About Avalo Therapeutics
關於Avalo Treateutics
(Get Rating)
(獲取評級)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics,Inc.是一家臨牀階段的精密藥物公司,為免疫學、免疫腫瘤學和罕見遺傳病方面未得到滿足的臨牀需求的患者發現、開發和商業化靶向療法。該公司開發了AVTX-002,這是一種完全人類抗光的單抗,正在進行第二階段臨牀試驗,用於治療非嗜酸性哮喘以及炎症性腸道疾病,包括中到重度克羅恩病和潰瘍性結腸炎;以及第三階段臨牀試驗,用於治療新冠肺炎急性呼吸窘迫綜合徵。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- After a $100 Haircut, is Catalent an Oversold Pharma Play?
- Is Tyson Foods Too Cheap To Ignore?
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- 免費獲取StockNews.com關於Avalo治療公司(AVTX)的研究報告
- 是時候與Joby Aviation的電動汽車創新一起兜風了嗎?
- 在100美元的理髮之後,Catalent是一個超賣的製藥公司嗎?
- 泰森食品是不是太便宜了,不容忽視?
- Alphabet股票提供難得的買入機會
- 太陽能電池製造商安相清理買入點位:漲勢能否守住?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Avalo治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。